Posts tagged EXEL


Exelixis, Inc.’s (EXEL) RCC Treatment Gets Early FDA Approval

Exelixis, Inc. (NASDAQ:EXEL) said on Tuesday that the FDA approved its┬áCABOMETYX tablets, for the expanded …

Top Analyst Pounds the Table on Exelixis, Inc. (EXEL)

Cowen’s Eric Schmidt sees an extra several hundred million dollars in sales for EXEL in HCC market.

Why Exelixis, Inc. (EXEL) Shares Took Off Today

Exelixis, Inc. (NASDAQ:EXEL) is a mover and shaker out on the Street today, with investors …

Exelixis, Inc. (EXEL) Focuses on CABOMETYX’s Label Expansion

Exelixis, Inc. (NASDAQ:EXEL) announced this morning that it has completed the submission of a supplemental …

William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)

Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys …

Biotech Beat: Arena Pharmaceuticals, Inc. (ARNA) and Exelixis, Inc. (EXEL)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) investors have a smile on their faces Monday evening, after the …

Show More